NEU-627 / Neuron23 - LARVOL DELTA

A Study to Assess NEU-627 in Healthy Participants (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Neuron23 Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulator. (PubMed, Proc Natl Acad Sci U S A) - "We deployed brain-penetrant TYK2 inhibitors (cTYK2i) alongside the peripherally restricted TYK2 inhibitor (pTYK2i; BMS-986165) to untangle the contributions of central TYK2 inhibition in diverse models of neuroinflammation. Finally, we demonstrate TYK2 inhibition has a robust impact on a unique subset of activated astrocytes termed Interferon-Responsive-Reactive-Astrocytes (IRRA). The data presented herein identify a key role for CNS TYK2 signaling in regulating neuroinflammation and solidify TYK2 as a potential therapeutic target for MS."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • TYK2

Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator (ECTRIMS 2024) - " We deployed our brain penetrant TYK2 inhibitors (cTYK2i) alongside the systemic TYK2 inhibitor (sTYK2i; BMS-986165) in diverse forms of EAE models to untangle the contributions of central TYK2 inhibition on EAE pathophysiology using selective pharmacology. The data presented herein suggests a key role for CNS TYK2 signaling in regulating neuroinflammation and solidifies TYK2 as a potential therapeutic target for MS."

CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • TYK2